Scienture Reports 216% Revenue Growth on Arbli Launch, Eyes REZENOPY Debut
Event summary
- Scienture reported 216% year-over-year revenue growth to $431,609 in 2025, driven by Arbli launch
- Arbli, a liquid losartan formulation, captured early traction in $241M U.S. losartan market
- REZENOPY, a high-dose naloxone nasal spray, set for Q2 2026 launch targeting $141M naloxone market
- Company posted $41.5M net loss in 2025, including $26.3M non-cash impairment charge
- Scienture seeks Nasdaq compliance extension by April 13, 2026
The big picture
Scienture's strong revenue growth reflects successful execution of its specialty pharmaceutical strategy, but its path to profitability remains uncertain. The company's focus on unmet medical needs in large markets positions it for long-term growth, though it must navigate regulatory compliance challenges and sustain commercial momentum. The upcoming REZENOPY launch could further diversify its revenue base, but execution risks remain.
What we're watching
- Commercial Momentum
- Whether Scienture can sustain Arbli's early market traction and capture meaningful share in the losartan market
- Regulatory Compliance
- The likelihood of Nasdaq granting Scienture's compliance extension request and the company's ability to meet listing requirements
- Pipeline Execution
- The pace at which Scienture advances its pipeline candidates, particularly SCN-102 for migraine and SCN-106 for thrombosis
Related topics